Mild cognitive impairment is a syndrome defined as cognitive decline greater than expected
for an individual's age and education level but that does not interfere notably with activities …

Background Mild cognitive impairment (MCI) due to Alzheimer's disease is the symptomatic
predementia phase of Alzheimer's disease dementia, characterised by cognitive and …

Background Avelumab (anti-programmed death ligand 1 (PD-L1)) is approved in multiple
countries for the treatment of metastatic Merkel cell carcinoma (mMCC), a rare and …

The Memory and Aging Project is a longitudinal, epidemiologic clinical-pathologic cohort
study of common chronic conditions of aging with an emphasis on decline in cognitive and …

The Religious Orders Study is a longitudinal clinical-pathologic cohort study of aging and
Alzheimer's disease (AD). In this manuscript, we summarize the study methods including the …

Magnetic resonance imaging (MRI) patterns were examined together with cerebrospinal
fluid (CSF) biomarkers in serial scans of Alzheimer's Disease Neuroimaging Initiative (ADNI) …

One of the major neuropathological findings in the brains of individuals with Alzheimer's
disease (AD) is a loss of synaptic contacts in both the neocortex and hippocampus. Here we …

Objective: A variety of measurements have been individually linked to decline in mild
cognitive impairment (MCI), but the identification of optimal markers for predicting disease …

Biomarkers of brain Aβ amyloid deposition can be measured either by cerebrospinal fluid
Aβ42 or Pittsburgh compound B positron emission tomography imaging. Our objective was …

The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a multi-center study assessing
neuroimaging in diagnosis and longitudinal monitoring. Amnestic Mild Cognitive Impairment …